Assessment of the Ovarian Cancer Landscape
Objective of the Study
Our client is a leading global and consulting company who wanted to understand the future ovarian cancer landscape, the formulary/reimbursement decision-making process, its influencers and how this process may affect treatment decisions in the US market.
Key Screening Points
- Healthcare professionals namely, Radiation Oncology experts, Chief Medical Officer, Gynaecology Oncologists, Medical Directors, Medical Oncologists and Haematology specialists were targeted.
- Respondents had to be licensed in at least 1 state of Oncology except Vermont, Massachusetts or Minnesota.
- Healthcare experts involved in formulary decision making or in advising P&T committees on formulary decisions for ovarian or other cancer drugs.